ANZCTR search results

This pilot randomized controlled trial will test whether virtual reality training can help clinicians feel more confident and successfully insert an IV on the first try using ultrasound guidance in the emergency department. The goal is to see if this training approach is practical and beneficial enough to justify a larger future study.

Preterm infants, particularly those born at less than 26 weeks gestational age, are highly vulnerable to skin injuries, which can lead to colonisation by pathogenic bacteria, sepsis, pain, and lifelong scarring. StrataCTX is a silicone polymer-based film-forming gel that creates a protective layer on the skin, promoting (re-)epithelialisation and healing. This gel shows promise in preventing skin injuries in preterm infants. The primary objective of this pilot trial is to evaluate the safety, feasibility, and preliminary efficacy of StrataCTX in preventing skin injuries in preterm infants compared to our standard care, topical coconut oil.

The study aims to access the feasibility of Pulsenmore’s home ultrasound technology in monitoring high-risk pregnancies at Gold Coast University Hospital, assessing whether home ultrasound monitoring can be effectively and reliable used in a clinical setting, in comparison to standard antenatal care only. The successful implementation of the home ultrasound remote monitoring may help to facilitate early detection of fetal compromise to prevent adverse outcomes for both mother and baby, as well as empower pregnant women via information sharing and support on self-performed assessments to facilitate respectful, woman-cantered care.

The purpose of this platform study is to assess the efficacy of teclistamab and talquetamab for patients who have functional high-risk disease, defined as relapsing or refractory within 18 months of first-line myeloma treatment. Patients who have functional high-risk disease currently do not have optimal treatments available via the Pharmaceutical Benefits Scheme and have poorer outcomes compared to myeloma patients who are not considered functional high-risk. Who is it for? You may be eligible for this study if you are male or female aged 18 years or older, have a documented diagnosis of multiple myeloma and have relapsed within 18 months following initiation of first-line therapy and require treatment. Study details Participants who choose to enrol in this domain of the ZEPFHR-MM platform trial will be administered two cancer treatment drugs (via an injection into the skin) for up to 24 treatment cycles. Each treatment cycle will continue for 28 days following the first drug dose and participants will be monitored to determine whether they are responding to the treatment or not. It is hoped this research will determine whether the combination of teclistamab and talquetamab cancer treatments is effective at slowing and/or stopping disease progression in patients with relapsing or refractory multiple myeloma. If this treatment is shown to be effective, it may be offered to a larger number of patients with multiple myeloma in the future.

This study is a continuous innovation study of the EMVision emu™ brain scanner for patients suspected of suffering from an acute stroke or intracranial haemorrhage for algorithm development purposes and indication expansion to traumatic brain injuries. This study collects EMVision brain scans and radiological scans from patients receiving brain imaging as part of their routine care. Scans are anonymised and enter the EMVision database for advancing and extending software algorithms. This study hypothesises that an expanded acute brain injury dataset can improve the diagnostic performance of the emu™ brain scanner and extend utility to patients suspected of intracranial haemorrhage following traumatic brain injury.

Peripheral intravenous catheters (PIVCs) are commonly used in neonatal care to deliver fluids and medications. However, due to the fragility of neonatal skin and veins, PIVCs are prone to failure, which may lead to treatment interruptions and additional procedures. Tissue adhesive is a medical-grade glue that has shown promise in improving PIVC securement in adult and paediatric populations, but there is limited high-quality evidence regarding its use in neonates. The PENGUIN trial is a two-arm pilot randomised controlled trial aiming to evaluate the feasibility of a larger effectiveness study on the use of tissue adhesive in neonatal PIVC securement. A total of 100 neonates requiring PIVC insertion will be enrolled and randomised to receive either: (i) standard care with a bordered polyurethane dressing, or (ii) standard care plus tissue adhesive applied at the insertion site. Randomisation will be stratified by age at enrolment (less than 15 days or equal and greater than 15 days of life). This trial will examine whether it is feasible, including the safety, to use tissue adhesive to secure PIVC in neonates. Findings will inform the design and safety of a larger future trial.

Study aims to evaluate the use of an Artificial Intelligence (AI) Scribe at the Queensland Children’s Hospital (QCH) and Childrens Health Queensland (CHQ) across medical, allied health and nursing professions in a cohort of users who were part of a quality improvement project with AI scribe. The study design is retrospective-prospective cohort design. The retrospective component of the study aims to analyse the data and the outcomes from the CHQ Digital AI Scribe (Quality Improvement) Proof of Concept Project in the clinicians onboarded for the Queensland Children's Hospital AI scribe quality improvement initiative (data upto first 2 months after onboarding as part of the quality improvement project). The prospective component of the study aims to evaluate the ouctomes for the same cohort of health professionals following completion of the Quality Improvement phase of the project beyond 2 months of onboarding (onboarding month is defined as the first month of AI scribe use when the user is learning to use the AI scribe)

Older women are at a much higher risk for osteoporosis (weak bones) and fracture, compared to men. When considering diet, often only calcium, vitamin D and protein are promoted for muscle and bone health. Yet an overall balanced diet is critical to optimise musculoskeletal health. In addition to protein, calcium and vitamin D, key nutrients from vegetables and fruits also play an important role. However, improving dietary habits, such as increasing fruit and vegetable intake, is challenging. To overcome this limitation, BoneBoost Gelato, a nutrient-dense, whole food ice cream containing a variety of key nutrients shown support musculoskeletal health, has been developed. This pilot study seeks to examine the effects of 4-weeks of daily BoneBoost Gelato consumption on markers of bone health in older women.

The current research project aims to examine the preliminary effectiveness and acceptability of an established online psychological intervention (referred to as the Chronic Conditions Course) for people struggling with the impacts of chronic health conditions. This intervention has been evaluated in several previous randomised controlled trials with hundreds of patients with mixed chronic health conditions. This specific trial is focused on Australian adults with atrial fibrillation (AF). The intervention aims to support people to learn psychological and other self-management skills to manage the impacts of chronic health conditions on their day-to-day lives and mental health. We hypothesise that we will observe significant improvements in Atrial Fibrillation related Quality-Of-Life, symptoms of anxiety and symptoms of depression. We hypothesise that the majority of participants (>70%) will be satisfied with the intervention.

The purpose of this platform study is to assess the efficacy of different novel treatments/ combinations for patients who have functional high-risk disease, defined as relapsing or refractory within 18 months of first-line myeloma treatment. Patients who have functional high-risk disease currently do not have optimal treatments available via the Pharmaceutical Benefits Scheme and have poorer outcomes compared to myeloma patients who are not considered functional high-risk. Who is it for? You may be eligible for this study if you are male or female aged 18 years or older, have a documented diagnosis of multiple myeloma and have relapsed within 18 months following initiation of first-line therapy and require treatment. Study details A platform study is designed to make the process of trialing different treatments for the same disease more efficient by making these treatments under one "platform" and therefore under one ethics approval. With the platform, there are different "domains", analogous to treatment arms. Your treating doctor will decide which domain is potentially suitable for you. Biological samples, such as blood and bone marrow, will be collected to assess how you respond to treatment. These samples will also be used for scientific research to better understand how myeloma changes after using these treatments. It is hoped that findings from this study will provide information on newer treatments that are not yet available in Australia to treatment functional high-risk myeloma.